top of page

Biopharma Daily Stock Updates - 12/15/21

$XBI $113.39 +4.25%%


Covid Updates

$CDXS +2.4% Codexis Launches Codex® HiTemp Reverse Transcriptase to Address Key Challenges in One-Step Assays for RNA Detection in PCR Testing, including COVID-19 Testing. source

$EIGR +2.6% Eiger BioPharmaceuticals Announces Second Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Patients. source

$OCGN +12.7% New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination. source

Pipeline Updates

$VRCA +2.3% Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum source

$EGRX +12.1% Eagle Pharmaceuticals Receives FDA Approval for Vasopressin source

$NKTR +2.2% Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Atopic Dermatitis. source

$EWTX +1.6% Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study. source

$YMAB +5.5% Y-mAbs Announces Pipeline Update. source

$ACRX +2.8% AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery. source

$SCYX +7.1% European Medicines Agency Grants Orphan Medicinal Product Designation for SCYNEXIS’ Innovative Antifungal Ibrexafungerp for the Indication of Invasive Candidiasis. source

$OTLK +4.3% Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia. source

$IMAB -4.9% I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China. source

$EXEL +5.1% Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors. source

$AVTE +16.3% Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension. source

$JAZZ +0.8% Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor. source

$HUMA -0.5% Humacyte Announces Publication Highlighting the First Use of the Human Acellular Vessel (HAV™) as Arterial Bypass Conduit for Replacement of Infected Prosthetic Graft. source

$NUVB +3.7% Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme. source

$TVTX +10.6% Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria. source

$APLS +4.0% Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH. source

Business Updates

$SNDX +6.7% Syndax Announces Proposed Public Offering of Common Stock source

$ATXI -10.8% Avenue Therapeutics Announces Closing of Public Offering of Common Stock source


Posted by JM/FS

bottom of page